Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Adenocarcinoma
Carcinoma
Esophageal neoplasms
Neoplasms
Proton pump inhibitors
Squamous cell
Stomach neoplasms
Journal
Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
25
06
2019
revised:
13
08
2019
accepted:
14
08
2019
pubmed:
25
8
2019
medline:
9
4
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
There is increasing interest in the potential association between proton pump inhibitors (PPIs) and the risk of gastric and oesophageal cancer, yet the effect of duration of treatment needs clarification. This Swedish population-based cohort study assessed the influence of time since initiation of PPI treatment on the risk of gastric and oesophageal cancer, presented as standardised incidence ratios and 95% confidence intervals. The risk of gastric and oesophageal cancer during the first year was 7-10 times higher than the background population, and remained 24-202% increased without any decrease over time after the first year. PPI use was associated with an increased risk of gastric and oesophageal cancer and the risk remained increased over follow-up. These results support our original hypothesis that use of PPIs may be a risk factor for gastric and oesophageal cancer in the general population of maintenance users, independent of underlying indications.
Sections du résumé
BACKGROUND
There is increasing interest in the potential association between proton pump inhibitors (PPIs) and the risk of gastric and oesophageal cancer, yet the effect of duration of treatment needs clarification.
METHODS
This Swedish population-based cohort study assessed the influence of time since initiation of PPI treatment on the risk of gastric and oesophageal cancer, presented as standardised incidence ratios and 95% confidence intervals.
RESULTS
The risk of gastric and oesophageal cancer during the first year was 7-10 times higher than the background population, and remained 24-202% increased without any decrease over time after the first year.
CONCLUSION
PPI use was associated with an increased risk of gastric and oesophageal cancer and the risk remained increased over follow-up. These results support our original hypothesis that use of PPIs may be a risk factor for gastric and oesophageal cancer in the general population of maintenance users, independent of underlying indications.
Identifiants
pubmed: 31445426
pii: S1877-7821(19)30096-7
doi: 10.1016/j.canep.2019.101585
pii:
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101585Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.